Atorvastatin Calcium Tablet
Product Images NDC 16571-139

8 FDA label images from Rising Pharma Holdings, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Atorvastatin Calcium (NDC 16571-139). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rising Pharma Holdings, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (B94c6347 161c 44f2 8937 34c5098bf755 01)

Image (B94c6347 161c 44f2 8937 34c5098bf755 01)
Chemical structure of atorvastatin calcium, showing the molecular arrangement including aromatic rings, fluorine, hydroxyl groups, and the calcium ion complex with associated water molecules, as depicted in the image.*
FDA Label Image

Image (B94c6347 161c 44f2 8937 34c5098bf755 02)

Image (B94c6347 161c 44f2 8937 34c5098bf755 02)
A line graph showing cumulative incidence (%) over time in years, comparing Atorvastatin and Placebo. The graph plots two curves, with Atorvastatin represented by a solid line and Placebo by a dashed line. The graph includes a hazard ratio (HR=0.64) with confidence intervals and a p-value (p=0.0005).*
FDA Label Image

Image (B94c6347 161c 44f2 8937 34c5098bf755 03)

Image (B94c6347 161c 44f2 8937 34c5098bf755 03)
A Kaplan-Meier cumulative hazard curve comparing Atorvastatin versus placebo over a 5-year follow-up period measuring time to first primary endpoint through four years. The plot shows a lower cumulative hazard percentage for Atorvastatin compared to placebo, with hazard ratio (HR) 0.63 (0.48-0.83), p=0.001.*
FDA Label Image

Image (B94c6347 161c 44f2 8937 34c5098bf755 04)

Image (B94c6347 161c 44f2 8937 34c5098bf755 04)
A line graph comparing the percentage of subjects experiencing a major cardiovascular event over time, from 0 to 5 years, for Atorvastatin 10 mg and Atorvastatin 80 mg. The graph shows two curves representing each dosage strength, with time to first major cardiovascular endpoint on the x-axis and percentage of subjects on the y-axis. Statistical data includes a hazard ratio of 0.78 and a p-value of 0.0002.*
FDA Label Image

90 Tablets (B94c6347 161c 44f2 8937 34c5098bf755 05)

90 Tablets (B94c6347 161c 44f2 8937 34c5098bf755 05)
Atorvastatin Calcium Tablets USP 10 mg film-coated tablets, 90 count, oral dosage form. The label shows the NDC 16571-136-09, manufactured by Graviti Pharmaceuticals Pvt. Ltd. in India, and distributed by Rising Pharma Holdings, Inc., East Brunswick, NJ. It includes storage instructions and a barcode.*
FDA Label Image

90 Tablets (B94c6347 161c 44f2 8937 34c5098bf755 06)

90 Tablets (B94c6347 161c 44f2 8937 34c5098bf755 06)
Atorvastatin Calcium Tablets USP 20 mg film-coated oral tablets packaging label from Rising Pharmaceuticals. The label specifies a bottle of 90 tablets, with an NDC of 16571-137-09. Manufactured by Graviti Pharmaceuticals Pvt. Ltd., India, and distributed by Rising Pharma Holdings, Inc., East Brunswick, NJ. Storage instructions and prescription-only indication are included.*
FDA Label Image

90 Tablets (B94c6347 161c 44f2 8937 34c5098bf755 07)

90 Tablets (B94c6347 161c 44f2 8937 34c5098bf755 07)
Atorvastatin Calcium Tablets USP 40 mg film-coated oral tablets, packaged in a bottle or container of 90 tablets. Label shows the product is distributed by Rising Pharma Holdings, Inc., with manufacturing by Graviti Pharmaceuticals Pvt. Ltd., India. The label states storage instructions and Rx-only status.*
FDA Label Image

90 Tablets (B94c6347 161c 44f2 8937 34c5098bf755 08)

90 Tablets (B94c6347 161c 44f2 8937 34c5098bf755 08)
Label for Atorvastatin Calcium Tablets, USP 80 mg by Rising Pharmaceuticals. The label states the pack contains 90 film-coated tablets. It includes storage instructions, indicates Rx only, and lists the manufacturer as Graviti Pharmaceuticals Pvt. Ltd., India, with distribution by Rising Pharma Holdings, Inc., East Brunswick, NJ.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.